Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

selpercatinib 2pembrolizumab 2abemaciclib 2Pemetrexed 2Nivolumab 2Irinotecan 2Fulvestrant 2Abiraterone Acetate 2ribociclib 1repotrectinib 1relatlimab 1pralsetinib 1pamiparib 1palbociclib 1osimertinib 1onapristone 1olaparib 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1exemestane 1enzalutamide 1elacestrant 1cobimetinib 1abiraterone 1Trastuzumab 1Taxes 1Tamoxifen 1STX-478 1Radiation 1RAD1901 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms by Site × ficlatuzumab × Clear all
NCT01039948 2015-04-08

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

AVEO Pharmaceuticals, Inc.

Phase 1/2 Completed
203 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡